Leerink Partners on Insmed (INSM): competitor data gives positive readthrough, continues re-rate

March 30, 2026 8:43 AM

Leerink Partners analyst Joseph P. Schwartz reiterated an Outperform rating and $215.00 price target on Insmed (NASDAQ: INSM)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found